NURIX THERAP. DL-,001

At the H.C. Wainwright conference Nurix highlighted the shift from platform research to late-stage development and emphasized strong phase I data for bexobrutideg with response rates of 80–90%. The partnership with Roche, signed in June, includes a $700 million upfront payment and up to $2.3 billion in milestones plus a 50/50 profit split in the U.S.; Roche will take over development and commercialization outside the U.S. Two registration-relevant trials are already underway (100 patients in late-line CLL, a 620-patient comparative study versus pirtobrutinib), while Nurix continues to expand its platform through collaborations with Sanofi, Gilead and Pfizer. » Más en de.investing.com

At the Wells Fargo conference, Nurix presented clinical progress of its BTK degrader bexobrutideg, reporting an 83% response rate and a median progression-free survival of 22.1 months in heavily pretreated CLL, and plans a phase III study versus pirtobrutinib. The 2024 collaboration with Roche includes a $700 million upfront payment and up to $2.3 billion in milestones; development costs will be split 40/60. The company is also advancing immunology programs for CSU and MS, expanding partnerships (Sanofi, Gilead, Pfizer), and sees future commercialization as contingent on demonstrating safety, selectivity, and durable efficacy. » Más en de.investing.com

Nurix Therapeutics' stock rose to a 52-week high of $26.40 and posted a one-year total return of 159% with a market capitalization of $2.72 billion; according to InvestingPro the stock is trading near its fair value. Analysts raised price targets after the Q2 report and the collaboration agreement with Roche (Mizuho, Truist, Baird, Morgan Stanley) and maintained positive ratings. InvestingPro predicts a return to profitability this year with an expected EPS of $3.80. » Más en de.investing.com